Galectin-3 inhibition, heavy metal chelation, and cancer support

How modified citrus pectin binds the inflammatory protein galectin-3 and removes heavy metals without stripping essential minerals

Modified citrus pectin (MCP) is regular citrus peel pectin that has been broken down — through controlled pH and heat treatment — into shorter, galactose-rich fragments small enough to cross from the gut into the bloodstream [1]. Once absorbed, these fragments bind tightly to galectin-3, a protein that promotes inflammation, tissue fibrosis, and the adhesion of cancer cells to blood vessel walls [1]. MCP also works in the gut itself, acting as a gentle binder that increases urinary excretion of lead, arsenic, cadmium, and mercury without significantly depleting essential minerals like calcium, zinc, or magnesium [2].

What galectin-3 does — and why blocking it matters

Galectin-3 is a lectin protein secreted by immune cells (primarily macrophages) when the body is under chronic stress. At low levels it plays helpful roles in immunity, but chronically elevated galectin-3 is associated with fibrosis of the heart, kidneys, and liver; progression of cardiovascular disease; cancer cell metastasis; and systemic inflammation [1]. It works partly by cross-linking cell-surface receptors, triggering a signaling cascade that promotes scarring and inflammatory gene expression.

MCP binds directly to galectin-3's carbohydrate recognition domain — the site the protein uses to interact with its cellular targets. By occupying that domain, MCP blocks downstream signaling without interfering with the protein's beneficial acute-immune functions [1]. Preclinical studies show reductions in cardiac and renal fibrosis markers, smaller atherosclerotic lesion areas, and inhibited cancer cell adhesion to endothelial tissue under MCP treatment.

The first randomized controlled trial in humans (n=56, people with hypertension and elevated galectin-3) found that MCP significantly lowered circulating galectin-3 levels over 6 months compared to placebo, though it did not produce statistically significant changes in echocardiographic measures of cardiac stiffness or collagen metabolism markers during that timeframe [3]. This suggests galectin-3 lowering with MCP is achievable in humans, but longer trials may be needed to see downstream structural changes.

Heavy metal chelation — gentler than EDTA

In a pilot study of six adults, participants took 15 g/day of MCP for 5 days and 20 g on day 6. Urinary arsenic excretion rose by approximately 130% on day 1 of supplementation, and by day 6, lead excretion had increased by around 560%, cadmium by about 150%, and mercury measurably as well. Critically, urinary calcium, magnesium, and zinc did not increase significantly, indicating that MCP selectively chelates toxic metals without short-term depletion of essential minerals [2].

This selectivity is a meaningful advantage over conventional chelation agents like EDTA, which can strip essential minerals and carry risks of kidney damage if not carefully managed. MCP appears to work primarily by binding metals in the gastrointestinal tract before systemic absorption, though some of its action may also occur in the bloodstream. It is not a replacement for pharmaceutical chelation in acute heavy metal poisoning, but for people with subclinical exposure (common via tap water, cookware, old paint, and certain foods), MCP offers a well-tolerated daily option.

Cancer support: PSA doubling time

The most studied oncological application is biochemically relapsed prostate cancer — cases where PSA rises after initial treatment but no detectable metastases are present. A prospective phase II study followed 40 patients taking 4.8 g of MCP three times daily for 6 months, then extended to 18 months in those without progression. At 6 months, 75% of patients showed a clinically meaningful improvement in PSA doubling time (PSADT) — the longer the PSADT, the slower the disease is progressing [4]. At 18 months of total treatment, disease stabilization was maintained in a substantial proportion of participants and quality-of-life scores improved.

The mechanism is thought to involve galectin-3 inhibition reducing cancer cell adhesion to vascular endothelium and dampening pro-growth signaling pathways. Preclinical studies also show MCP can inhibit cancer cell aggregation and reduce metastatic lesion formation in animal models of breast, colon, and melanoma cancers.

Dosage and practical use

Most human studies use 5–15 g/day of MCP, typically divided into two or three doses and taken on an empty stomach or 30 minutes before meals to maximize absorption before food competes with it. For heavy metal support, 15 g/day for 5-day pulses is the protocol most studied. For galectin-3 inhibition and cancer support, the phase II trials used 14.4 g/day long-term.

MCP is generally well tolerated. The most common side effects are mild GI symptoms — bloating or loose stools — particularly at higher doses, which tend to resolve within the first week. Because it is a form of soluble fiber, it should be taken with adequate water.

Brand quality matters. Not all pectin products labeled "modified" have been processed to the degree needed for systemic absorption and galectin-3 binding. The product used in most published studies (PectaSol-C) has been validated for the short-chain galactose-rich structure required for bioactivity.

See our heavy metal detox page for context on common sources of toxic metal exposure and testing options, and our activated charcoal page for a comparison with other binders.

Evidence Review

Galectin-3 inhibition — mechanistic evidence and the first human RCT

The pleiotropic effects review by Eliaz and Raz (2019) provides the most comprehensive synthesis of MCP's mechanisms across disease models [1]. Galectin-3 inhibition has been demonstrated in cell culture studies of cardiac fibroblasts, kidney tubular cells, endothelial cells, and multiple cancer cell lines. In apolipoprotein E-deficient atherosclerosis mouse models, oral MCP reduced atherosclerotic lesion area, associated with decreased macrophage and smooth muscle cell infiltration. In experimental acute kidney injury models, MCP reduced galectin-3 expression and attenuated fibrotic remodeling.

The first human randomized placebo-controlled trial (Lau et al., 2021; n=56) recruited adults with hypertension and elevated galectin-3 levels (>17.8 ng/mL) [3]. Over 6 months, MCP (15 g/day) produced a statistically significant reduction in serum galectin-3 compared to placebo. However, pre-specified secondary endpoints — changes in procollagen type I C-terminal propeptide (PICP), procollagen type III N-terminal propeptide (PIIINP), echocardiographic left ventricular stiffness parameters, and flow-mediated dilation — did not reach significance. The authors noted the trial was likely underpowered for structural endpoints, which require longer timeframes to show measurable change, and called for longer-duration trials.

Heavy metal chelation — clinical evidence

Eliaz et al. (2006) conducted an open-label pilot study in five adults (n=5, no control group) using standardized MCP at 15–20 g/day over 6 days [2]. Twenty-four-hour urine collections were compared against baseline. The results showed:

Day 1: Arsenic +130% (p < 0.05)
Day 6: Lead +560% (p < 0.05), Cadmium +150% (p < 0.05), Mercury increased (specific percentage not reported in abstract)
Essential minerals (calcium, zinc, magnesium): no significant change

The sample size (n=5) limits conclusions, and the absence of a control group means natural fluctuation in urinary metal excretion cannot be ruled out. However, the magnitude of change for lead is notable. A separate published case series described children with clinical lead poisoning given MCP as an adjunct to standard DMSA chelation; the cases reported accelerated lead clearance, though the methodological rigor of that report is lower than a controlled trial.

Prostate cancer — phase II findings

Keizman et al. (2023) published 18-month follow-up data from a phase II study of 40 men with non-metastatic biochemically relapsed prostate cancer [4]. Patients received PectaSol-C at 4.8 g three times daily (14.4 g/day total). Key findings:

At 6 months: PSADT improvement (defined as lengthening) in 75% of evaluable patients
At 18 months (extended treatment arm, n=27): continued disease stabilization in the majority; no new metastases in a significant proportion
Quality of life (FACT-P score): improved from baseline at both time points
Tolerability: generally good; adverse events were mostly grade 1 GI symptoms

This was a single-arm, non-randomized study — there is no placebo control, so some of the PSADT improvement could reflect natural fluctuation. Nonetheless, the consistency of the signal over 18 months and the improvement in quality-of-life scores support further investigation. A randomized phase III trial would be needed to confirm MCP as a standard supportive intervention in this setting.

Strength of evidence overall

The mechanistic rationale for MCP is well-supported by preclinical data across multiple disease models. Human evidence is in early stages: one RCT (hypertension, showing galectin-3 reduction but not downstream structural effects at 6 months) and phase II oncology data (single-arm, promising but not definitive). Heavy metal chelation data in humans comes from a small open-label study. MCP appears safe and well-tolerated at studied doses. For people with documented elevated galectin-3, high toxic metal burden, or as supportive care in oncology contexts, the risk-benefit profile is favorable given the safety data. For otherwise healthy individuals without known elevations in these targets, the evidence base does not yet support routine prophylactic supplementation.

References

Pleiotropic Effects of Modified Citrus PectinEliaz I, Raz A. Nutrients, 2019. PubMed 31683865 →
The effect of modified citrus pectin on urinary excretion of toxic elementsEliaz I, Hotchkiss AT, Fishman ML, Rode D. Phytotherapy Research, 2006. PubMed 16835878 →
Galectin-3 Inhibition With Modified Citrus Pectin in HypertensionLau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, López B, Díez J, Wang TJ, Ho JE. JACC: Basic to Translational Science, 2021. PubMed 33532663 →
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II StudyKeizman D, Frenkel M, Peer A, Rosenbaum E, Sarid D, Leibovitch I, Mano R, Yossepowitch O, Wolf I, Geva R, Margel D, Rouvinov K, Stern A, Dresler H, Kushnir I, Eliaz I. Nutrients, 2023. PubMed 37630724 →